Axinn is pleased to represent McKesson Corporation (NYSE: MCK), a leading, diversified health care services company, as lead antitrust counsel on its acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash, which will represent approximately 70% ownership. Announced on August 26, the Core Ventures transaction is part of McKesson’s efforts to advance community-based oncology care, seeking to bring advanced treatments and improved outcomes to patients, while also reducing the overall cost of care. Core Ventures was established by Florida Cancer Specialists (FCS), a leading physician-owned community oncology practice, and Core Ventures serves as its exclusive provider of non-clinical business and other administrative services. FCS will join McKesson’s The U.S. Oncology Network, a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes.

The Axinn antitrust team is led by partners Jeny Maier and Daniel Bitton, and assisted by counsel Carol Liu and Michael O'Mara.